162 related articles for article (PubMed ID: 36916193)
1. Therapy-related Myeloid Neoplasms Following PARP Inhibitors-Letter.
Batalini F; Mina LA; Mina A
Clin Cancer Res; 2023 Mar; 29(6):1157. PubMed ID: 36916193
[No Abstract] [Full Text] [Related]
2. Therapy-related myeloid neoplasms following treatment with PARP inhibitors: new molecular insights.
Martin JE; Khalife-Hachem S; Grinda T; Kfoury M; Garciaz S; Pasquier F; Vargaftig J; Uzunov M; Belhabri A; Bertoli S; Cotteret S; Vergé V; Renneville A; Rosselli F; Antony-Debre I; Rouleau E; Salviat F; Caron O; Delaloge S; Pautier P; Etienne G; Recher C; Vey N; De Botton S; Leary A; Marzac C; Micol JB
Ann Oncol; 2021 Aug; 32(8):1046-1048. PubMed ID: 34107346
[No Abstract] [Full Text] [Related]
3. Therapy-related Myeloid Neoplasms Following PARP Inhibitors-Response.
Marmouset V; Morice PM; Pagès A; Leary A; Micol JB
Clin Cancer Res; 2023 Mar; 29(6):1158-1159. PubMed ID: 36916192
[No Abstract] [Full Text] [Related]
4. Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers.
Przybycinski J; Nalewajska M; Marchelek-Mysliwiec M; Dziedziejko V; Pawlik A
Expert Opin Ther Targets; 2019 Sep; 23(9):773-785. PubMed ID: 31394942
[No Abstract] [Full Text] [Related]
5. Secondary haematologic malignancies in women with ovarian cancer receiving poly-ADP ribose polymerase inhibitor therapy.
Matsuo K; Klar M; Mohrbacher AF; Roman LD; Wright JD
Eur J Cancer; 2021 Nov; 157():59-62. PubMed ID: 34487985
[No Abstract] [Full Text] [Related]
6. Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action.
Pommier Y; O'Connor MJ; de Bono J
Sci Transl Med; 2016 Oct; 8(362):362ps17. PubMed ID: 27797957
[TBL] [Abstract][Full Text] [Related]
7. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
8. [Poly (ADP-Ribose) Polymerase Inhibitors--Current Status and Future Developments].
Yoshida H; Fujiwara K
Gan To Kagaku Ryoho; 2016 Feb; 43(2):193-7. PubMed ID: 27093730
[No Abstract] [Full Text] [Related]
9. Poly-ADP-ribose polymerase (PARP) inhibitors and ovarian function.
Li J; Li Q; Zhang L; Zhang S; Dai Y
Biomed Pharmacother; 2023 Jan; 157():114028. PubMed ID: 36410122
[TBL] [Abstract][Full Text] [Related]
10. Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy.
Gourley C; Balmaña J; Ledermann JA; Serra V; Dent R; Loibl S; Pujade-Lauraine E; Boulton SJ
J Clin Oncol; 2019 Sep; 37(25):2257-2269. PubMed ID: 31050911
[TBL] [Abstract][Full Text] [Related]
11. Response to letter to the editor "AML and MDS associated with PARP inhibitor treatment of ovarian cancer".
O'Malley DM; Ledermann JA; Coleman RL
Gynecol Oncol; 2023 Apr; 171():164-165. PubMed ID: 36774327
[No Abstract] [Full Text] [Related]
12. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
Henning RJ; Bourgeois M; Harbison RD
Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072
[TBL] [Abstract][Full Text] [Related]
13. Differences in PARP Inhibitors for the Treatment of Ovarian Cancer: Mechanisms of Action, Pharmacology, Safety, and Efficacy.
Valabrega G; Scotto G; Tuninetti V; Pani A; Scaglione F
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921561
[TBL] [Abstract][Full Text] [Related]
14. Novel poly-ADP-ribose polymerase inhibitor combination strategies in ovarian cancer.
McCann KE
Curr Opin Obstet Gynecol; 2018 Feb; 30(1):7-16. PubMed ID: 29251678
[TBL] [Abstract][Full Text] [Related]
15. Movement of Poly-ADP Ribose (PARP) Inhibition into Frontline Treatment of Ovarian Cancer.
Onstad M; Coleman RL; Westin SN
Drugs; 2020 Oct; 80(15):1525-1535. PubMed ID: 32852746
[TBL] [Abstract][Full Text] [Related]
16. Current status and progress in using radiolabelled PARP-1 inhibitors for imaging PARP-1 expression in tumours.
Wang Q; Zhang J
Eur J Med Chem; 2022 Nov; 242():114690. PubMed ID: 36041258
[TBL] [Abstract][Full Text] [Related]
17. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
Parkes EE; Kennedy RD
Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety updates of poly ADP-ribose polymerase (PARP) inhibitor maintenance in ovarian cancer from ASCO 2020.
Madariaga A; Bonilla L; McMullen M; Oza AM; Lheureux S
Int J Gynecol Cancer; 2020 Aug; 30(8):1256-1257. PubMed ID: 32646863
[No Abstract] [Full Text] [Related]
19. [PARP inhibitors--theoretical basis and clinical application].
Dębska S; Kubicka J; Czyżykowski R; Habib M; Potemski P
Postepy Hig Med Dosw (Online); 2012 May; 66():311-21. PubMed ID: 22706117
[TBL] [Abstract][Full Text] [Related]
20. Research progress on the association between environmental pollutants and the resistance mechanism of PARP inhibitors in ovarian cancer.
Zhou L; Xiang J; He Y
Environ Sci Pollut Res Int; 2021 Sep; 28(36):49491-49506. PubMed ID: 34370190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
